GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Last week, Australia ’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

It was only a matter of time until the GLP-1 receptor agonist drugs like ... and now it looks like we'll have the next generation of these breakthrough weight loss and diabetes medicines on ...

America's famous drug manufacturer Eli Lilly has launched the weight loss ... Now its availability in India is expected to provide great relief to patients suffering from obesity and type-2 diabetes.